Last update Oct. 16, 2006

Dihydroergocristine Mesilate

Very High Risk

Very unsafe. Contraindicated. Use of an alternative or cessation of breastfeeding. Read the Comment.

Ergot-derivative alkaloid with an inhibiting effect on prolactin and dopamine release, used for treatment of brain vascular insufficiency and senile dementia. It may suppress lactation by inhibiting prolactin release.

Nonessential drug.

Alternatives

We do not have alternatives for Dihydroergocristine Mesilate.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Group

Dihydroergocristine Mesilate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Dihydroergocristine Mesilate in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 708 daltons

References

  1. [No authors listed] Do not use drugs to prevent onset of lactation. Relieve the discomfort and wait. Prescrire Int. 2013 Abstract

Total visits

5,684

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM